Literature DB >> 21167733

Factors for development of late significant tricuspid regurgitation after mitral valve replacement: the impact of subvalvular preservation.

Rafael García Fuster1, Alejandro Vázquez, Aritz García Peláez, Elio Martín, Sergio Cánovas, Oscar Gil, Fernando Hornero, Juan Martínez-León.   

Abstract

OBJECTIVE: Development of late significant tricuspid regurgitation (TR) after successful mitral valve replacement (MVR) is not infrequent. The impact of different aetiologies or diverse surgical procedures has not been adequately investigated. We studied the influence of subvalvular preservation techniques during MVR on the incidence of late TR.
METHODS: A total of 801 patients with grade ≤ 2+/4+ preoperative TR underwent MVR without associated tricuspid procedures from January 1994 to August 2008. In 595 patients, only posterior mitral leaflet preservation was performed (group A). In the remaining 206 patients, both anterior and posterior leaflets were retained (group B). Postoperative development of significant TR was defined as a TR increase by more than one grade from preoperative or final TR grade ≥ 3+/4+ at follow-up.
RESULTS: The global incidence of postoperative significant TR was 8.6%, with higher incidence in females (9.4% vs 6.7%, p=0.12), rheumatic disease (9.7% vs 6.5%, p=0.07), patients with previous AF (11.8% vs 3.8%, p<0.001) and, especially, in group A (10.8% vs 2.4%, p<0.001). The Maze procedure was protective in patients with AF (the incidence with and without associated Maze was 6.7% vs 13.2%, p=0.04). Preoperative left-atrial diameters were higher in patients with postoperative development of TR (56 ± 9 mm vs 51 ± 12 mm, p=0.01). Group A (p=0.04) and preoperative atrial fibrillation (p=0.001) were significant predictors of late postoperative TR. Late functional TR decreased free survival from chronic heart failure.
CONCLUSIONS: Several clinical and operative factors are associated with the development of significant TR after MVR. Although early surgical intervention for TR may be recommended in selected patients, complete subvalvular preservation of the mitral valve and routine surgical ablation of atrial fibrillation can significantly reduce its incidence.
Copyright © 2010 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 21167733     DOI: 10.1016/j.ejcts.2010.11.014

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  5 in total

Review 1.  Tricuspid regurgitation: pathophysiology and management.

Authors:  Rashmi Thapa; Buddhadeb Dawn; Jayant Nath
Journal:  Curr Cardiol Rep       Date:  2012-04       Impact factor: 2.931

2.  Predictive factor of secondary tricuspid regurgitation after aortic valve replacement for aortic stenosis: the importance of myocardial hypertrophy and diastolic dysfunction.

Authors:  Takashi Igarashi; Masahiro Tanji; Koki Takahashi; Keiichi Ishida; Satomi Sasaki; Hitoshi Yokoyama
Journal:  Gen Thorac Cardiovasc Surg       Date:  2017-02-26

3.  Concomitant tricuspid valve repair in patients with minimally invasive mitral valve surgery.

Authors:  Bettina Pfannmüller; Piroze Davierwala; Gregor Hirnle; Michael A Borger; Martin Misfeld; Jens Garbade; Joerg Seeburger; Friedrich W Mohr
Journal:  Ann Cardiothorac Surg       Date:  2013-11

4.  Impact and evolution of right ventricular dysfunction after successful MitraClip implantation in patients with functional mitral regurgitation.

Authors:  Cosmo Godino; Anna Salerno; Michela Cera; Eustachio Agricola; Gabriele Fragasso; Isabella Rosa; Michele Oppizzi; Alberto Monello; Andrea Scotti; Valeria Magni; Matteo Montorfano; Alberto Cappelletti; Alberto Margonato; Antonio Colombo
Journal:  Int J Cardiol Heart Vasc       Date:  2016-05-09

5.  Surgical management of tricuspid regurgitation: a new algorithm to minimise recurrent tricuspid regurgitation.

Authors:  Diego Rodriguez Torres; Lucía Torres Quintero; Diego Segura Rodríguez; Jose Manuel Garrido Jimenez; Maria Esteban Molina; Francisco Gomera Martínez; Eduardo Moreno Escobar; Rocio Garcia Orta
Journal:  Open Heart       Date:  2022-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.